PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
Open Access
- 5 July 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0200014
Abstract
Glioblastoma (GBM) is the most common adult primary brain tumor. Multimodal treatment is empiric and prognosis remains poor. Recurrent PIK3CA missense mutations (PIK3CAmut) in GBM are restricted to three functional domains: adaptor binding (ABD), helical, and kinase. Defining how these mutations influence gliomagenesis and response to kinase inhibitors may aid in the clinical development of novel targeted therapies in biomarker-stratified patients. We used normal human astrocytes immortalized via expression of hTERT, E6, and E7 (NHA). We selected two PIK3CAmut from each of 3 mutated domains and induced their expression in NHA with (NHARAS) and without mutant RAS using lentiviral vectors. We then examined the role of PIK3CAmut in gliomagenesis in vitro and in mice, as well as response to targeted PI3K (PI3Ki) and MEK (MEKi) inhibitors in vitro. PIK3CAmut, particularly helical and kinase domain mutations, potentiated proximal PI3K signaling and migration of NHA and NHARAS in vitro. Only kinase domain mutations promoted NHA colony formation, but both helical and kinase domain mutations promoted NHARAS tumorigenesis in vivo. PIK3CAmut status had minimal effects on PI3Ki and MEKi efficacy. However, PI3Ki/MEKi synergism was pronounced in NHA and NHARAS harboring ABD or helical mutations. PIK3CAmut promoted differential gliomagenesis based on the mutated domain. While PIK3CAmut did not influence sensitivity to single agent PI3Ki, they did alter PI3Ki/MEKi synergism. Taken together, our results demonstrate that a subset of PIK3CAmut promote tumorigenesis and suggest that patients with helical domain mutations may be most sensitive to dual PI3Ki/MEKi treatment.Keywords
Funding Information
- National Cancer Institute (R01CA204136)
- National Center for Advancing Translational Sciences (UL1TR001111)
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
- National Institute of Environmental Health Sciences (P30ES010126)
- National Cancer Institute (P30CA016086)
This publication has 55 references indexed in Scilit:
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Glioblastoma: From Molecular Pathology to Targeted TreatmentAnnual Review of Pathology: Mechanisms of Disease, 2014
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Personalizing Oncology: Perspectives and ProspectsJournal of Clinical Oncology, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The PI3K Pathway As Drug Target in Human CancerJournal of Clinical Oncology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005